ANS Eon cleared
This article was originally published in The Gray Sheet
Executive Summary
Second-generation rechargeable implantable pulse generator (IPG) earns FDA approval for managing chronic intractable pain of the trunk and/or limbs "earlier than expected," CEO Chris Chavez notes March 15. Advanced Neuromodulation Systems will start selling the device on a limited basis in Q2, with a full market launch planned in the second half of 2005. The firm already markets the Genesis RX and RC Dual IPG systems. Eon will compete with Boston Scientific's Precision and Medtronic's Itrel spinal cord stimulation devices (1"The Gray Sheet" Feb. 7, 2005, p. 4). ANS claims the battery life "usage time" of its IPG - seven years at high-power settings - lasts up to two years longer than that of competitors. The firm may pursue extended battery-life claims in the future...